Daniel Ricklin, Ph.D.
Daniel Ricklin, Ph.D.
Research Assistant Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Contact information
401 Stellar Chance
422 Curie Blvd.
Philadelphia, PA 19104
422 Curie Blvd.
Philadelphia, PA 19104
Office: 215-746-5760
Fax: 215-573-8738
Lab: 215-746-5767
Fax: 215-573-8738
Lab: 215-746-5767
Email:
ricklin@upenn.edu
ricklin@upenn.edu
Publications
Education:
M.Sc. (Pharmaceutical Sciences)
Swiss Federal Institute of Technology (ETH), Zurich, Switzerland, 1999.
Ph.D. (Pharmaceutical Chemistry, Biophysics)
University of Basel, Switzerland, 2005.
Permanent linkM.Sc. (Pharmaceutical Sciences)
Swiss Federal Institute of Technology (ETH), Zurich, Switzerland, 1999.
Ph.D. (Pharmaceutical Chemistry, Biophysics)
University of Basel, Switzerland, 2005.
Description of Research Expertise
The primary focus of my research efforts is on the molecular elucidation of the role of the human complement system in health and disease. In recent years, a body of research has impressively demonstrated that the function of the complement system reaches far beyond the detection and elimination of microbial intruders but covers a broad range from immune modulation and metabolism to cell development and homeostasis, which require a highly tailored and context-specific response. Using an integrated approach based on biophysical (e.g., surface plasmon resonance), biochemical, structural, and cell-based techniques, my goal is to shed light into the underlying processes of complement activation and regulation, as well as to describe its molecular connections to associated physiological pathways. At the same time, it has become evident that any disruption of the careful balance between activation and regulation may contribute to pathological processes, and a number of complement-related diseases have been described in recent years and put complement-directed drug discovery into the spotlight. At the same time, complement is also involved in adverse effects observed in connection with the emerging field of biomaterials in modern medicine (e.g., implants, drug delivery devices). One aspect of my research therefore focuses on the discovery and development of potent inhibitors that allow for a therapeutic modulation of the complement cascade at various stages, and on the evaluation of such inhibitors in clinically relevant models. Finally, I am investigating the fascinating immune evasion mechanisms that human pathogens developed through millennia of co-evolution with their host. Focusing on Staphylococcus aureus, I examine various bacterial inhibitors directed against complement and other immune pathways, and explore their implications on immune activity and their potential as templates for therapeutics.Selected Publications
Garcia BL, Ramyar KX, Tzekou A, Ricklin D, McWhorter WJ, Lambris JD, Geisbrecht BV.: Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3. Journal of Molecular Biology 402(1): 17-29, Sept 2010.Ricklin D, Chen H, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, Wu YQ, Tzekou A, Li S, Geisbrecht BV, Woods VL Jr, Lambris JD.: Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America 107(41): 17621-6, Oct 2010.
Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, Nilsson Ekdahl K.: Contribution of chondroitin sulfate a to the binding of complement proteins to activated platelets. PLoS One 5(9): e12889, Sept 2010.
Magotti P, Ricklin D, Qu H, Wu YQ, Kaznessis YN, Lambris JD: Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition 22(6): 495-505, Nov-Dec 2009.
Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD: A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. Journal of Immunology 183(4): 2565-74, Aug 2009.
Wu J, Wu YQ, Ricklin D, Janssen BJC, Lambris JD, Gros P: Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nature Immunology 10(7): 728-33, Jul 2009.
Rooijakkers SHM, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJC, van Strijp JAG, Gros P: Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nature Immunology 10(7): 721-7, Jul 2009.
Ricklin D, Petrou PS, Zavali M, Raptis I, Kakabakos SE, Misiakos K, Lambris JD: Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. Biosensors & Bioelectronics 24(11): 3359-64, Jul 2009.

